Atezolizumab is a humanized monoclonal antibody that works by inhibiting the interaction between PD-L1 (on tumor cells) and PD-1 (on T cells), leading to upregulation of the immune response against tumor cells. This evidence concerns the gene CD274 and neoplasm.